0001384101-21-000155.txt : 20210909 0001384101-21-000155.hdr.sgml : 20210909 20210909170735 ACCESSION NUMBER: 0001384101-21-000155 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210907 FILED AS OF DATE: 20210909 DATE AS OF CHANGE: 20210909 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kennedy Giulia C CENTRAL INDEX KEY: 0001769333 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36156 FILM NUMBER: 211245104 MAIL ADDRESS: STREET 1: 338 MAIN STREET #26E CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERACYTE, INC. CENTRAL INDEX KEY: 0001384101 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 205455398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 243-6300 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: CALDEROME INC DATE OF NAME CHANGE: 20061219 4 1 wf-form4_163122163694896.xml FORM 4 X0306 4 2021-09-07 0 0001384101 VERACYTE, INC. VCYT 0001769333 Kennedy Giulia C 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific & Med Officer Common Stock 2021-09-07 4 M 0 4406 5.98 A 55381 D Common Stock 2021-09-07 4 M 0 3750 20.21 A 59131 D Common Stock 2021-09-07 4 M 0 4375 24.69 A 63506 D Common Stock 2021-09-07 4 S 0 12034 50.519 D 51472 D Common Stock 2021-09-07 4 S 0 497 51.233 D 50975 D Common Stock 2021-09-08 4 S 0 926 50.53 D 50049 D Stock Option (right to buy) 5.98 2021-09-07 4 M 0 4406 0 D 2028-03-01 Common Stock 4406.0 8813 D Stock Option (right to buy) 20.21 2021-09-07 4 M 0 3750 0 D 2029-02-27 Common Stock 3750.0 22500 D Stock Option (right to buy) 24.69 2021-09-07 4 M 0 4375 0 D 2030-03-27 Common Stock 4375.0 43750 D The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Represents weighted average sales price. Sale prices for the transactions range from $50.06 to $51.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $51.07 to $51.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. /s/ Jane Alley as attorney-in-fact 2021-09-09